Unlabelled: Low-grade gliomas (LGGs) may harbor malignant foci, which are characterized by increased tumor cellularity and angiogenesis. We used diffusion-weighted MR imaging (apparent diffusion coefficient [ADC]) and PET with the amino acid O-(2-(18)F-fluorethyl)-L-tyrosine ((18)F-FET) to search for focal changes of diffusion (ADC) and amino acid uptake and to investigate whether focal changes in these parameters colocalize within LGGs.
Methods: We retrospectively selected 18 patients with nonenhancing LGG. All patients had undergone (18)F-FET PET and MR imaging for preoperative evaluation or for therapy monitoring in recurrent or progressive LGG. Region-of-interest analysis was performed to compare (18)F-FET uptake and ADC values in areas with focal intratumoral maximum metabolic activity and diffusion restriction and between tumor and normal brain. (18)F-FET uptake was normalized to the mean cerebellar uptake (ratio). ADC values were also compared with the (18)F-FET uptake on a voxel-by-voxel basis across the whole tumor.
Results: The mean focal maximum (mean ± SD, 1.69 ± 0.85) and global (18)F-FET uptake in tumors (1.14 ± 0.41) exceeded that of normal cortex (0.85 ± 0.09) and cerebrospinal fluid (0.82 ± 0.20). ADC values in the area with most restricted diffusion (1.07 ± 0.22 × 10(-3) mm(2)/s) and in the whole tumor (1.38 ± 0.27 × 10(-3) mm(2)/s) were in the range between normal cortex (0.73 ± 0.06 × 10(-3) mm(2)/s) and cerebrospinal fluid (2.84 ± 0.09 × 10(-3) mm(2)/s). (18)F-FET uptake did not correlate with corresponding (colocalizing) ADC values, either in the area with focal maximum metabolic activity or in the area with most restricted diffusion or in the whole tumor.
Conclusion: There is no congruency between (18)F-FET uptake and diffusivity in nonenhancing LGG. Diffusion restriction in these tumors most likely represents changes in brain and tumor cell densities as well as alteration of water distribution and is probably not directly correlated with the density of tumor cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.113.130732 | DOI Listing |
Neuro Oncol
January 2025
Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Background: Recently, criteria based on amino acid positron emission tomography (PET) have been proposed for response assessment in diffuse gliomas (PET RANO 1.0). In this study, we compare the prevalence of measurable disease according to PET RANO 1.
View Article and Find Full Text PDFMol Pharm
June 2024
Forschungszentrum Jülich GmbH, Nuclear Chemistry (INM-5), Institute of Neuroscience and Medicine, Wilhelm-Johnen-Straße, Jülich 52428, Germany.
-([F]Fluoroethyl)-l-tyrosine ([F]FET) is actively transported into the brain and cancer cells by LAT1 and possibly other amino acid transporters, which enables brain tumor imaging by positron emission tomography (PET). However, tumor delivery of this probe in the presence of competing amino acids may be limited by a relatively low affinity for LAT1. The aim of the present work was to evaluate the -substituted [F]FET analog -[F]FET and the methyl ester [F]FET-OMe, which were designed to improve tumor delivery by altering the physicochemical, pharmacokinetic, and/or transport properties.
View Article and Find Full Text PDFClin Cancer Res
April 2024
Cancer Research UK Scotland Institute, Garscube Estate, Glasgow, United Kingdom.
Purpose: The current approach for molecular subtyping of colon cancer relies on gene expression profiling, which is invasive and has limited ability to reveal dynamics and spatial heterogeneity. Molecular imaging techniques, such as PET, present a noninvasive alternative for visualizing biological information from tumors. However, the factors influencing PET imaging phenotype, the suitable PET radiotracers for differentiating tumor subtypes, and the relationship between PET phenotypes and tumor genotype or gene expression-based subtyping remain unknown.
View Article and Find Full Text PDFJ Nucl Med
February 2024
Department of Surgery and Cancer, Imperial College London, London, United Kingdom;
There is a clinical need for F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [F]fluoroethyl-triazole-[Tyr]-octreotate ([F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [F]FET-βAG-TOCA PET/CT compared with [Ga]Ga-DOTA- peptide PET/CT in patients with NET.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
March 2024
Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Helmholtz-Zentrum Dresden-Rossendorf, Research site Leipzig, Leipzig, Germany.
Glioma are clinically challenging tumors due to their location and invasiveness nature, which often hinder complete surgical resection. The evaluation of the isocitrate dehydrogenase mutation status has become crucial for effective patient stratification. Through a transdisciplinary approach, we have developed an F-labeled ligand for non-invasive assessment of the IDH1R132H variant by using positron emission tomography (PET) imaging.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!